机械取栓术中辅助全身低温治疗(ReCCLAIM II):一项多中心、随机、对照试验
这项在美国10个中心进行的II期随机可行性对照试验纳入95例前循环大血管闭塞患者,评估取栓术中经血管内冷却导管诱导全身低温的可行性。治疗组33例中91%在动脉穿刺后1小时内达到低温,70%在再灌注前达到目标温度,门-再灌注时间与对照组无显著差异,最终梗死体积数值上较低但未达统计学显著,严重不良事件在低温组较多。
要点
- 治疗组91%在动脉穿刺后1小时内达到低温,70%在再灌注前达目标温度<34°C。
- 门-再灌注时间低温组95分钟 vs 对照组94分钟,无显著差异(P=0.70)。
- 最终梗死体积低温组11 cm³ vs 对照组30 cm³,数值较低但未达统计学显著(P=0.13)。
核心结论
- 这是首个证明在机械取栓术中早期快速全身低温作为辅助治疗可行且不延迟再灌注时间的临床试验。
- 低温对梗死体积和严重不良事件的潜在影响需进一步研究。
研究设计与样本
- II期随机可行性对照试验,在美国10个中心开展,时间为2019年5月至2024年5月。
- 纳入标准为近端大脑中动脉或颈内动脉闭塞、Alberta卒中项目早期CT评分6至10分、症状发作24小时内。
- 患者接受机械取栓并随机分配至新型血管内冷却导管辅助低温治疗组或标准治疗组。
- 共纳入95例患者,其中导入期29例,随机化66例。
- 随机队列平均年龄65±12岁,美国国立卫生研究院卒中量表评分中位数15分。
主要发现
- 治疗组33例中30例(91%)在取栓术中动脉穿刺后1小时内达到低温。
- 治疗组33例中23例(70%)在再灌注前达到目标温度(<34°C)。
- 低温诱导中位时间为动脉穿刺后10分钟(四分位距7–22分钟)。
- 门-再灌注时间低温组95分钟(四分位距54–116)vs 对照组94分钟(四分位距77–121),P=0.70,无显著差异。
- 最终梗死体积低温组11 cm³(四分位距5–42)vs 对照组30 cm³(四分位距6–80),P=0.13。
局限性
- 试验未针对严重不良事件或临床疗效差异进行效力计算。
- 低温对梗死体积和严重不良事件的潜在影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke, Ahead of Print. BACKGROUND:Hypothermia reduces ischemic injury in preclinical stroke models, yet translation into the clinical setting remains challenging. We aimed to assess the feasibility of inducing adjuvant systemic hypothermia among patients with large-vessel occlusion stroke during mechanical thrombectomy.METHODS:This was a phase II randomized feasibility-controlled trial involving 10 sites in the United States, conducted between May 2019 and May 2024. All eligible patients had confirmed proximal middle cerebral artery or internal carotid artery occlusions, an Alberta Stroke Program Early Computed Tomography Score of 6 to 10, and symptom onset within 24 hours. Patients underwent mechanical thrombectomy and were randomly assigned to either treatment with adjuvant hypothermia using a novel intravascular cooling catheter or standard of care. The primary feasibility end points were the ability to achieve a target temperature of <34 °C within 1 hour of arterial puncture and overall door-to-reperfusion times. The primary safety end point was core-laboratory-adjudicated hemorrhagic conversion within 36 hours, and secondary end points included final infarct volume and serious adverse events.RESULTS:A total of 95 patients were enrolled (29 in the roll-in phase and 66 randomized). The mean age of the randomized cohort was 65±12 years, with a median National Institutes of Health Stroke Scale score of 15. Among patients in the treatment arm, 30 of 33 (91%) achieved hypothermia within 1 hour of arterial puncture during thrombectomy, and 23 of 33 (70%) patients were at target temperature (<34 °C) before reperfusion. The median time to hypothermia was 10 minutes (interquartile range [IQR], 7–22) from arterial puncture. There were no significant differences in door-to-reperfusion times (hypothermia: 95 minutes [IQR, 54–116] versus control: 94 minutes [IQR, 77–121];P=0.70). Final infarct volumes were numerically lower in the hypothermia treatment arm (hypothermia: 11 cm3[IQR, 5–42] versus control: 30 cm3[IQR, 6–80];P=0.13), with no significant differences in the rates of hemorrhagic conversion or pneumonia. There was a higher number of serious adverse events in the hypothermia arm (45.5% versus 24.2%;P=0.12), although the trial was not powered for differences in serious adverse events or clinical efficacy.CONCLUSIONS:This is the first clinical trial to demonstrate the feasibility of early and rapid systemic hypothermia as an adjunct therapy during mechanical thrombectomy without delaying time to reperfusion. The potential impact on infarct volumes and serious adverse events, however, warrants further investigation. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03804060.
引用
- Stroke:Adjuvant Systemic Hypothermia During Mechanical Thrombectomy (ReCCLAIM II): A Multicenter, Randomized, Controlled Trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。